Advanced Magnetics Inc., of Cambridge, Mass., appointed Michael Avallone chief financial officer.
Agensys Inc., of Santa Monica, Calif., appointed Martha Vincent vice president of clinical research and development.
Allegent Technology Group, of Woodbury, N.Y., appointed Ralph Sheridan to its board of advisers.
ART Advanced Research Technologies Inc., of Montreal, appointed Martin Yaffe chairman of its scientific advisory board.
Astralis Ltd., of Fairfield, N.J., elected Sam Barnett and Philippe Magistretti to its board.
AtheroGenics Inc., of Atlanta, appointed Peter Libby to its scientific advisory board.
Australian Cancer Technology, of Sydney, Australia, appointed Philip Livingston to its scientific advisory board.
Beyond Genomics Inc., of Waltham, Mass., formed a research and development advisory board consisting of Arnold Levine and Jeffrey Friedman as co-chairs, and David Jackson, Jan van der Greef, Victor Dzau, Marc Kirschner, Douglas Lauffenburger and Christopher Sander as members.
Biosite Inc., of San Diego, appointed Bill Ferenczy vice president of marketing.
Biovail Corp., of Toronto, appointed John Sebben vice president of global manufacturing.
Ciphergen Biosystems Inc., of Fremont, Calif., promoted Eric Fung to vice president of clinical and medical affairs in its diagnostics division.
Codexis, of Redwood City, Calif., appointed James Lalonde head of biocatalysts and chemical development.
Corgentech Inc., of South San Francisco, appointed Patrick Broderick vice president, general counsel and corporate secretary.
Cytomedix Inc., of Little Rock, Ark., appointed David Drohan to its board.
CytRx Corp., of Los Angeles, appointed Matthew Natalizio chief financial officer.
Dendreon Corp., of Seattle, appointed Linda Staley vice president of information technology.
DeVries Public Relations, of New York, appointed Paul Oestreicher as head of its health care practice.
DuPont, of Wilmington, Del., appointed Kevin Fitzgerald and Sven Thormahlen to its biotechnology advisory panel.
Enzo Biochem Inc., of Farmingdale, N.Y., named Marcus Conant to its board.
Exactech Inc., of Gainesville, Fla., appointed Bruce Thompson senior vice president and general manager, Exactech Biologics.
Forward Ventures, of San Diego, named David Urso a principal of the firm.
Fulcrum Pharmaceuticals Inc., of Las Vegas, appointed Douglas Gessl vice president of finance.
ID Biomedical, of Vancouver, British Columbia, appointed John Trizzino senior vice president of business development.
Immunicon Corp., of Huntingdon Valley, Pa., appointed Michael Kagan vice president, operations.
ImmunoGen Inc., of Cambridge, Mass., appointed Robert Fram head of its new clinical department.
INC Research, of Raleigh, N.C., appointed Bruce Brennan to its board.
MediciNova Inc., of San Diego, appointed Richard Gammans executive vice president, clinical research.
Point Therapeutics Inc., of Boston, appointed Richard Benjamin to its board.
PPD Inc., of Wilmington, N.C., appointed Colin Shannon executive vice president of global clinical operations.
Quaker BioVentures, of Philadelphia, appointed Thomas Amick to its advisory board.
Schering AG, of Berlin, appointed Karin Dorrepaal to its board.
Trigen Ltd., of London, appointed Ashley Tapp head of corporate communications.
Vaxin Inc., of Birmingham, Ala., appointed Alf Lindberg to its board.
Velcura Therapeutics Inc., of Ann Arbor, Mich., appointed Holly Britt Anderson laboratory/office administrator and Jessica Eason-Butler staff scientist.
WITA GmbH, of Teltow, Germany, appointed Hanns-Rudiger Graack and Thomas Pohl managing directors.